TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7943832

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (0.2, 0.8, 1.5, 3.0, and 4.5 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (0.63 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (1 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (3 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (greater than 3 ng/ml)
Number of subjects: 56
Study: 3791604

Group type: EXPERIMENTAL
Intervention: VVI-Act pacing
Number of subjects: 44

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 44
Study: 31519265

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Foot Massage
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control
Number of subjects: 139
Study: 28708736

Group type: EXPERIMENTAL
Intervention: Mifepristone 1200 mg daily for 7 days
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 24993290

Group type: EXPERIMENTAL
Intervention: Internet treatment
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Face-to-face treatment
Number of subjects: 395
Study: 23354007

Group type: EXPERIMENTAL
Intervention: Psychological and pharmacological interventions
Number of subjects: 670
Study: 21771216

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 16
Study: 19067101

Group type: EXPERIMENTAL
Intervention: Adalimumab in early RA
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Adalimumab in established RA
Number of subjects: 407
Study: 17705687

Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg twice-daily for 28 days
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg twice-daily for 4 weeks followed by 10 microg for 26 weeks
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 15498183

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times daily for 3 months (Group Aa)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clomiphene 50 mg once daily from the 5th day of menstrual cycle for 5 days and 3 cycles (Group Ab)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene for 3 cycles (Group Ac)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Metformin only (Group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clomiphene 50 mg once daily for 5 days and 3 cycles (Group Ab)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene (Group Ac)
Number of subjects: 70
Study: 11133901

Group type: EXPERIMENTAL
Intervention: Alpha-blocker (3 mg/day prazosin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9620105

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral sulfonylureas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 8131544

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally 3 times a day for 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro NAC treatment at 10 micrograms/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2675219

Group type: EXPERIMENTAL
Intervention: Morphine (50 micrograms/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%, 2.5 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no drug administered)
Number of subjects: 28
Study: 817373

Group type: EXPERIMENTAL
Intervention: Synthetic TRH (300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 30963820

Group type: EXPERIMENTAL
Intervention: EMPATHY questionnaire (group 1, 150 patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (group 2, 150 patients)
Number of subjects: 300
Study: 28367636

Group type: EXPERIMENTAL
Intervention: Automated closed-loop glucose control for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sensor augmented insulin pump therapy (open loop) for 12 weeks
Number of subjects: 58
Study: 25040098

Group type: EXPERIMENTAL
Intervention: 3% praziquantel (PZQ) ointment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (vehicle ointment)
Number of subjects: 65
Study: 23514023

Group type: EXPERIMENTAL
Intervention: Anterior flap anastomosis and excision of the posterior flap (Group B)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Anterior and posterior flap anastomosis (Group A)
Number of subjects: 83
Study: 20560804

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 60
Study: 19120432

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp) 0.3 U/kg
Number of subjects: 19
Study: 17434267

Group type: EXPERIMENTAL
Intervention: HIV/HCV prevention intervention trial
Number of subjects: 3128

Group type: EXPERIMENTAL
Intervention: Perceived risk of infection with HIV
Number of subjects: 3128

Group type: EXPERIMENTAL
Intervention: Perceived risk of infection with HCV
Number of subjects: 3128

Group type: EXPERIMENTAL
Intervention: Peer influences
Number of subjects: 3128

Group type: EXPERIMENTAL
Intervention: Injection partner type
Number of subjects: 3128
Study: 15179339

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 100
Study: 11471396

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contemporary Treatment Approach (CTA)
Number of subjects: 20
Study: 9693393

Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (12.5 mg, i.v.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral clomipramine after i.v. challenge
Number of subjects: 29
Study: 8968295

Group type: EXPERIMENTAL
Intervention: Salbutamol (SAL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Terbutaline (TER)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fenoterol (FEN)
Number of subjects: 21
Study: 2126915

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms, topical corticosteroid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg, cyclooxygenase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7029293

Group type: EXPERIMENTAL
Intervention: VAC plus ADR
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: VAC plus RT
Number of subjects: 264

Group type: COMPARATOR
Intervention: VAC
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Bilateral pulmonary RT
Number of subjects: 264
Study: 30651149

Group type: EXPERIMENTAL
Intervention: New regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional treatment regimen with second-line drugs including injectables for 20-24 months.
Number of subjects: 204
Study: 28657700

Group type: EXPERIMENTAL
Intervention: Test dentifrice (3.75% potassium chloride)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reference dentifrice (standard fluoride)
Number of subjects: 133
Study: 25978822

Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs) for reducing heavy drinking
Number of subjects: 6768

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6768
Study: 24509422

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluoroscopic-guided injection
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 28
Study: 22515336

Group type: EXPERIMENTAL
Intervention: Dismembered Anderson-Hynes (A-H) pyeloplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nondismembered Y-V pyeloplasty
Number of subjects: 50
Study: 20547296

Group type: EXPERIMENTAL
Intervention: Program X intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 18606285

Group type: EXPERIMENTAL
Intervention: Rumble strips on both sides of the center line
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sealed shoulders
Number of subjects: 43

Group type: COMPARATOR
Intervention: Actual marking (center line)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Other treatments (painted center line, post-delineators)
Number of subjects: 43
Study: 15811482

Group type: EXPERIMENTAL
Intervention: Vasopressor group (33 patients) with controlled fluid administration
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo group (32 patients) with fluid administration only
Number of subjects: 65
Study: 11821456

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SDC)
Number of subjects: 635
Study: 11149796

Group type: EXPERIMENTAL
Intervention: Permanent magnetic field therapy (magnets in the form of patches)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham magnet patches (control group)
Number of subjects: 20
Study: 8828946

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prednisolone (P)
Number of subjects: 40
Study: 1591463

Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched placebo tablet
Number of subjects: 10
Study: 6377715

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of immunoglobulins (Intragam)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no immunoglobulin administration)
Number of subjects: 50
Study: 30958901

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 664

Group type: COMPARATOR
Intervention: DMF
Number of subjects: 664
Study: 29330083

Group type: EXPERIMENTAL
Intervention: Pediatric weight management program delivered in the Healthy Weight Clinics of two federally qualified health centers (FQHC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Weight and Your Child programs delivered in two YMCAs
Number of subjects: 0
Study: 24037036

Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 16

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 16
Study: 22968252

Group type: EXPERIMENTAL
Intervention: Diet and Resistance Training (DRT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Diet-Only (DO)
Number of subjects: 137
Study: 21360473

Group type: EXPERIMENTAL
Intervention: Advised walking group (AWG)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supervised walking group (SWG)
Number of subjects: 18
Study: 19416932

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Timolol monotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dorzolamide-timolol combination to Timolol monotherapy
Number of subjects: 20
Study: 17803343

Group type: EXPERIMENTAL
Intervention: Topiramate monotherapy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Topiramate adjunctive therapy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Topiramate (100-200 mg/day)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 320
Study: 15163108

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 5
Study: 11256837

Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU) (450 mg/m2) and leucovorin (20 mg/m2) for five consecutive days during the first and fifth weeks of radiation therapy (50.4 Gy) (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral doxifluridine (700 mg/m2/day) and leucovorin (20 mg/m2) daily during radiation treatment (n = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral doxifluridine
Number of subjects: 28
Study: 8447616

Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol 1000 mg given orally shortly before surgery
Number of subjects: 834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study: 3780584

Group type: COMPARATOR
Intervention: 4 l Golytely (GOL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Balanced Electrolyte Solution (BES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GOL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BES
Number of subjects: 70
Study: 29704964

Group type: EXPERIMENTAL
Intervention: Group-based Habit Reversal Training (HRT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Education
Number of subjects: 28
Study: 26540369

Group type: EXPERIMENTAL
Intervention: Telehealth system (wireless wristwatch-based monitoring device, weight scale, blood pressure cuff, tablet) used for 6 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Weight scale
Number of subjects: 41
Study: 24742658

Group type: EXPERIMENTAL
Intervention: elevated cFLC (>57.2 mg/L)
Number of subjects: 352
Study: 23404485

Group type: EXPERIMENTAL
Intervention: 14 h training on a portable laparoscopic simulator over a 3 week period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control with no training
Number of subjects: 20
Study: 20496736

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with ginger moxibustion at Dazhui (GV 14) and Feishu (BL 13) applied once at specified intervals based on seasonal timing.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with ginger moxibustion at Dazhui (GV 14) and Feishu (BL 13) applied once every other 10 days during 30 days.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Quality of life and serum level of IL-13 before and after treatment in all groups.
Number of subjects: 71
Study: 18644206

Group type: EXPERIMENTAL
Intervention: Cannabis use treatment
Number of subjects: 160
Study: 16249929

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) alone
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) with 20 microg of pertussis toxoid (DTaP20)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) with 40 microg of pertussis toxoid (DTaP40)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) with 20 microg or 40 microg of pertussis toxoid
Number of subjects: 502

Group type: COMPARATOR
Intervention: Diphtheria-tetanus vaccine (DT) alone or with pertussis toxoid
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT)
Number of subjects: 502
Study: 12692474

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study: 10906502

Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 49

Group type: COMPARATOR
Intervention: IUD (Nova‐T)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mesigyna and IUD
Number of subjects: 49
Study: 8665578

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg (2 x 25 mg)
Number of subjects: 30
Study: 1449335

Group type: EXPERIMENTAL
Intervention: Enoximone 100 mg three times a day orally (Group E)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enoximone (Group E)
Number of subjects: 30
Study: 3713181

Group type: EXPERIMENTAL
Intervention: Bogus pipeline method
Number of subjects: 220

Group type: COMPARATOR
Intervention: Self-reported group
Number of subjects: 220
Study: 29862945

Group type: EXPERIMENTAL
Intervention: MPT64 patch test
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo patch test
Number of subjects: 512
Study: 26899529

Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 30
Study: 24831401

Group type: EXPERIMENTAL
Intervention: Neurovascular bundle preservation (NBP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional thoracotomy (CT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (NBP and CT)
Number of subjects: 40
Study: 24041300

Group type: EXPERIMENTAL
Intervention: Truflex articulating stylet
Number of subjects: 154

Group type: COMPARATOR
Intervention: Portex malleable stylet
Number of subjects: 154
Study: 21729789

Group type: EXPERIMENTAL
Intervention: Intracranial angioplasty and stenting
Number of subjects: 451

Group type: COMPARATOR
Intervention: Aggressive medical management
Number of subjects: 451
Study: 19027046

Group type: EXPERIMENTAL
Intervention: Cell-culture-derived influenza vaccine (CCIV)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional egg-based vaccine
Number of subjects: 240
Study: 16918618

Group type: EXPERIMENTAL
Intervention: 1% p-phenylenediamine (PPD) exposure for 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequent but longer duration and higher concentration exposure to PPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent, short duration, and lower concentration exposure to PPD
Number of subjects: 0
Study: 15327583

Group type: EXPERIMENTAL
Intervention: 600 mg of Alpha-lipoic acid (ALA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intra-arterial ALA (incremental cumulative doses of 0.5, 1.0, 1.5 and 2.0 mg ml(‐1) min(‐1))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Plasma ALA after oral supplementation
Number of subjects: 16
Study: 10899500

Group type: EXPERIMENTAL
Intervention: Repronex SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repronex IM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pergonal IM
Number of subjects: 0
Study: 9066509

Group type: EXPERIMENTAL
Intervention: Bioresonance therapy (BIT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham (placebo) BIT treatment
Number of subjects: 32
Study: 8453795

Group type: EXPERIMENTAL
Intervention: Cicaprost 2.5 micrograms tds
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cicaprost 5 micrograms tds
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 3005384

Group type: EXPERIMENTAL
Intervention: Captopril, 200 mg every 12 hours (n = 9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril maleate, 20 mg every 12 hours (n = 11)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril with hydrochlorothiazide, 25 mg every 12 hours (days 16 to 28)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide, 25 mg every 12 hours (days 16 to 28)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined use of captopril and enalapril
Number of subjects: 20
Study: 29699887

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 22
Study: 27094522

Group type: EXPERIMENTAL
Intervention: HUK (0.15 Perinatal Assessment Unit/day) for 7 consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine medication
Number of subjects: 30
Study: 25041141

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action Liquid
Number of subjects: 14

Group type: COMPARATOR
Intervention: CVS brand antacid
Number of subjects: 14
Study: 21967854

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1.4 g EPA and DHA)
Number of subjects: 34
Study: 20355261

Group type: EXPERIMENTAL
Intervention: Medical management (MM) + placebo
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Medical management (MM) + naltrexone
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Medical management (MM) + naltrexone + acamprosate
Number of subjects: 1383

Group type: COMPARATOR
Intervention: 6 of the 9 treatments
Number of subjects: 1383
Study: 18723909

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal betamethasone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single course of antenatal betamethasone
Number of subjects: 76
Study: 15994623

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (ethinyl estradiol 20 microg and levonorgestrel 100 microg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Number of subjects: 76
Study: 12022461

Group type: EXPERIMENTAL
Intervention: Internal pin channel with #330 bur
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Internal pin channel with #329 bur
Number of subjects: 48

Group type: COMPARATOR
Intervention: No internal retentive features
Number of subjects: 48
Study: 10604250

Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated plasma
Number of subjects: 49

Group type: COMPARATOR
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both SD-treated plasma and FFP
Number of subjects: 49
Study: 8566861

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Omeprazole + Ranitidine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 43
Study: 2007669

Group type: EXPERIMENTAL
Intervention: Terbinafine, 250 mg twice daily for 6 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Griseofulvin, 500 mg twice daily for 6 weeks
Number of subjects: 31
Study: 6126907

Group type: EXPERIMENTAL
Intervention: Alprazolam (n=30)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 50
Study: 31088207

Group type: EXPERIMENTAL
Intervention: Dance intervention (single session of physical activity)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sedentary group (control)
Number of subjects: 34
Study: 27871083

Group type: EXPERIMENTAL
Intervention: C-Flex (pressure relief CPAP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: C-Flex (maximum pressure relief setting)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fixed CPAP
Number of subjects: 24